RU2016121850A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2016121850A3 RU2016121850A3 RU2016121850A RU2016121850A RU2016121850A3 RU 2016121850 A3 RU2016121850 A3 RU 2016121850A3 RU 2016121850 A RU2016121850 A RU 2016121850A RU 2016121850 A RU2016121850 A RU 2016121850A RU 2016121850 A3 RU2016121850 A3 RU 2016121850A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361900919P | 2013-11-06 | 2013-11-06 | |
| US201361900878P | 2013-11-06 | 2013-11-06 | |
| US201361900946P | 2013-11-06 | 2013-11-06 | |
| US61/900,878 | 2013-11-06 | ||
| US61/900,946 | 2013-11-06 | ||
| US61/900,919 | 2013-11-06 | ||
| PCT/US2014/064441 WO2015069956A2 (fr) | 2013-11-06 | 2014-11-06 | Nouvelles formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016121850A RU2016121850A (ru) | 2017-12-08 |
| RU2016121850A3 true RU2016121850A3 (fr) | 2018-08-08 |
| RU2691951C2 RU2691951C2 (ru) | 2019-06-19 |
Family
ID=53042097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016121850A RU2691951C2 (ru) | 2013-11-06 | 2014-11-06 | Новые составы |
Country Status (14)
| Country | Link |
|---|---|
| US (8) | US9949991B2 (fr) |
| EP (3) | EP3065728A4 (fr) |
| JP (4) | JP6535338B2 (fr) |
| KR (1) | KR20160079109A (fr) |
| CN (3) | CN112402434A (fr) |
| AU (2) | AU2014346682B2 (fr) |
| CA (1) | CA2929821A1 (fr) |
| ES (1) | ES2834131T3 (fr) |
| HK (1) | HK1224228A1 (fr) |
| IL (1) | IL245420B (fr) |
| MX (2) | MX2016006012A (fr) |
| RU (1) | RU2691951C2 (fr) |
| SG (1) | SG11201604153UA (fr) |
| WO (3) | WO2015069961A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013169939A2 (fr) | 2012-05-08 | 2013-11-14 | Aeromics, Llc | Nouveaux procédés |
| WO2015069961A1 (fr) | 2013-11-06 | 2015-05-14 | Aeromics, Llc | Nouveaux sels de promédicament |
| RU2018144043A (ru) * | 2016-05-13 | 2020-06-15 | Аэромикс, Инк. | Кристаллы |
| JP2021023226A (ja) * | 2019-08-06 | 2021-02-22 | 学校法人慶應義塾 | アクアポリン活性調節剤候補のハイスループットスクリーニング方法 |
| CN110790787B (zh) * | 2019-11-12 | 2022-06-14 | 广东药科大学 | 一类水溶性前药、其制备方法及其作为药物的用途 |
| CN117337182A (zh) * | 2020-08-05 | 2024-01-02 | 江苏先声药业有限公司 | 一种水通道蛋白抑制剂的药物组合物及其制备方法 |
| CN117105810B (zh) * | 2023-10-23 | 2024-02-09 | 中国农业大学 | 一种具有广谱抗菌活性的化合物及其抗菌组合物 |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE615511A (fr) | 1961-03-25 | |||
| NL292958A (fr) | 1962-05-29 | 1900-01-01 | ||
| GB8809205D0 (en) | 1988-04-19 | 1988-05-25 | Nye P C G | Treatment of oedema |
| US5137871A (en) | 1989-07-28 | 1992-08-11 | Regents Of The University Of California | Treatment to reduce edema for brain and musculature injuries |
| DE4010536A1 (de) * | 1990-04-02 | 1991-10-10 | Boehringer Mannheim Gmbh | Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure |
| US5486530A (en) | 1991-04-27 | 1996-01-23 | Boehringer Mannheim Gmbh | Use of torasemide for the treatment of brain oedemas |
| DE4113820A1 (de) | 1991-04-27 | 1992-10-29 | Boehringer Mannheim Gmbh | Verwendung von torasemid zur behandlung von hirnoedemen |
| US5858702A (en) | 1991-12-13 | 1999-01-12 | The Johns Hopkins University | Isolation, cloning and expression of transmembrane water channel Aquaporin 5 (AQP5) |
| US5741671A (en) | 1991-12-12 | 1998-04-21 | The Johns Hopkins University | Isolation cloning and expression of transmembrane water channel aquaporin 1(AQP1) |
| US5519035A (en) | 1993-07-02 | 1996-05-21 | Cornell Research Foundation, Inc. | Treatment of stroke or in anticipation of the occurrence of brain ischemia |
| US20060167110A1 (en) | 1995-01-13 | 2006-07-27 | Blume Cherly D | Methods for treating cerebrovascular disease by administering desmethylselegiline |
| WO1998021951A1 (fr) | 1996-11-18 | 1998-05-28 | Emisphere Technologies, Inc. | Procede et composition pour induire une tolerance orale chez les mammiferes |
| WO1999007382A1 (fr) | 1997-08-06 | 1999-02-18 | Smithkline Beecham Corporation | Antagonistes des recepteurs des monocytes macrophages pouvant etre utilises pour traiter les maladies vasculaires |
| US5905090A (en) | 1998-04-29 | 1999-05-18 | Italfarmaco S.P.A. | Analogues of the active metabolite of leflunomide |
| CO5180581A1 (es) | 1999-09-30 | 2002-07-30 | Pfizer Prod Inc | Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia |
| US6500809B1 (en) | 1999-11-12 | 2002-12-31 | Neuron Therapeutics, Inc. | Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith |
| ES2211460T3 (es) | 1999-12-10 | 2004-07-16 | Pfizer Inc. | Compuestos de 1,4-dihidropiridina sustituidos con un heteroalrilo de 5 miembros como antagonistas de la bradiquinina. |
| UA82827C2 (en) | 2000-12-18 | 2008-05-26 | Inhibitors against the production and release of inflammatory cytokines | |
| US8980952B2 (en) | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
| AU2003222020B2 (en) | 2002-03-20 | 2008-08-28 | University Of Maryland Baltimore | A non-selective cation channel in neural cells and methods for treating brain swelling |
| CA2487891A1 (fr) | 2002-06-05 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Inhibiteurs de l'activation de ap-1 et de nfat |
| JPWO2003103648A1 (ja) | 2002-06-05 | 2005-10-06 | 株式会社医薬分子設計研究所 | 糖尿病治療薬 |
| CN1658854A (zh) | 2002-06-05 | 2005-08-24 | 株式会社医药分子设计研究所 | 免疫关联蛋白激酶抑制剂 |
| JP4743382B2 (ja) * | 2002-06-06 | 2011-08-10 | 株式会社医薬分子設計研究所 | Ｏ−置換ヒドロキシアリール誘導体 |
| CA2488367A1 (fr) | 2002-06-06 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Anti-allergique |
| US20060089395A1 (en) * | 2002-06-10 | 2006-04-27 | Susumu Muto | Nf-kb activation inhibitors |
| CA2488974A1 (fr) | 2002-06-10 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Medicament pour le traitement du cancer |
| EA011707B1 (ru) | 2002-06-11 | 2009-04-28 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. | Лекарственное средство для лечения нейродегенеративных заболеваний |
| CN1681487A (zh) | 2002-07-15 | 2005-10-12 | 美瑞德生物工程公司 | 化合物、组合物及其使用方法 |
| WO2004068928A2 (fr) | 2003-02-06 | 2004-08-19 | Uutech Limited | Peptides et utilisations de ceux-ci |
| DE602004002585T2 (de) | 2003-05-01 | 2007-10-25 | Innogene Kalbiotech Pte. Ltd. | Laktathaltige pharmazeutische Zusammensetzung und deren Verwendungen |
| CN100406006C (zh) | 2003-07-16 | 2008-07-30 | 株式会社医药分子设计研究所 | 皮肤色素沉着的治疗剂 |
| CN1886393A (zh) | 2003-10-08 | 2006-12-27 | 沃泰克斯药物股份有限公司 | 含有环烷基或吡喃基基团的atp－结合弹夹转运蛋白的调控剂 |
| US8467876B2 (en) | 2003-10-15 | 2013-06-18 | Rmx, Llc | Breathing disorder detection and therapy delivery device and method |
| WO2005039556A1 (fr) | 2003-10-29 | 2005-05-06 | Institute Of Medicinal Molecular Design. Inc. | Medicament permettant de prevenir et/ou de traiter la restenose ou la reocclusion apres un retablissement de la circulation sanguine |
| EP1691817A2 (fr) | 2003-12-02 | 2006-08-23 | Corgentech, Inc. | MOLECULES LEURRES OLIGONUCLEOTIDIQUES NF-kB |
| ATE486606T1 (de) | 2004-09-18 | 2010-11-15 | Univ Maryland | Therapeutische mittel zum targeting des ncca-atp- kanals und verwendungsverfahren dafür |
| AU2005287090A1 (en) | 2004-09-18 | 2006-03-30 | Department Of Veterans Affairs | Therapeutic agents targeting the NCca-ATP channel and methods of use thereof |
| US7601745B2 (en) | 2004-09-27 | 2009-10-13 | 4Sc Ag | Heterocyclic NF-kB inhibitors |
| WO2006074127A2 (fr) | 2005-01-04 | 2006-07-13 | Novartis Ag | Biomarqueurs permettant d'identifier l'efficacite du tegaserod chez des patients souffrant de constipation chronique |
| MY147790A (en) | 2005-04-28 | 2013-01-31 | Takeda Pharmaceutical | Stable emulsion composition |
| WO2007084464A2 (fr) | 2006-01-17 | 2007-07-26 | The University Of North Carolina At Chapel Hill | Inhibiteurs de canaux hydriques et leurs procédés d'utilisation |
| JP4273235B2 (ja) * | 2006-06-01 | 2009-06-03 | 国立大学法人 新潟大学 | アクアポリン４阻害薬 |
| WO2007143689A2 (fr) | 2006-06-06 | 2007-12-13 | Genentech, Inc. | Compositions et procédés destinés à moduler le développement vasculaire |
| KR20090027227A (ko) | 2006-06-06 | 2009-03-16 | 제넨테크, 인크. | 항-ｄｌｌ4 항체 및 이의 사용 방법 |
| US7671058B2 (en) | 2006-06-21 | 2010-03-02 | Institute Of Medicinal Molecular Design, Inc. | N-(3,4-disubstituted phenyl) salicylamide derivatives |
| US20100056444A1 (en) | 2006-10-12 | 2010-03-04 | Sven Martin Jacobson | Treatment of Alzheimer's Disease Using Compounds that Reduce the Activity of Non Selective Ca Activated ATP- Sensitive Cation Channels Regulated by SUR1 Receptors |
| US10004703B2 (en) | 2006-10-12 | 2018-06-26 | Biogen Chesapeake Llc | Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels |
| WO2008052190A2 (fr) | 2006-10-26 | 2008-05-02 | Flynn Gary A | Modulateurs d'aquaporine et procédés pour leur utilisation pour le traitement d'un oedème et d'un déséquilibre de fluides |
| WO2008067196A2 (fr) | 2006-11-16 | 2008-06-05 | The Regents Of The University Of California | Procédés permettant d'identifier des inhibiteurs de transporteurs de soluté |
| US20080171719A1 (en) | 2006-11-28 | 2008-07-17 | Alcon Manufacturing, Ltd. | RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS |
| US20080214486A1 (en) | 2006-11-28 | 2008-09-04 | Alcon Manufacturing, Ltd. | RNAi-MEDIATED INHIBITION OF AQUAPORIN 4 FOR TREATMENT OF IOP-RELATED CONDITIONS |
| CA2674949A1 (fr) | 2007-01-12 | 2008-07-24 | J. Marc Simard | Ciblage de canal ncca-atp destine a proteger les organes apres un episode ischemique |
| CA2675638C (fr) | 2007-01-16 | 2015-11-24 | Ipintl, Llc | Composition comprenant de la serotonine pour traiter le syndrome metabolique |
| US20120183600A1 (en) * | 2007-01-16 | 2012-07-19 | Chien-Hung Chen | Novel composition for treating metabolic syndrome and other conditions |
| US20100092469A1 (en) | 2007-02-09 | 2010-04-15 | Simard J Marc | Antagonists of a non-selective cation channel in neural cells |
| EP2124539A2 (fr) | 2007-02-17 | 2009-12-02 | President and Fellows of Harvard College | Compositions et procede de conservation de tissu |
| WO2008133884A2 (fr) | 2007-04-23 | 2008-11-06 | Combinatorx, Incorporated | Procédés et compositions pour traiter des maladies neurodégénératives |
| CA2691199C (fr) | 2007-06-22 | 2017-09-12 | Marc J. Simard | Inhibiteurs de canaux nc<sb>ca-atp</sb> pour therapie |
| EP2178531A4 (fr) | 2007-07-02 | 2012-01-11 | Yu Ming | Méthodes et compositions, cibles pour les traitements combinés du cancer |
| US20090239868A1 (en) | 2007-10-23 | 2009-09-24 | Institute Of Medical Molecular Design, Inc. | Inhibitor of pai-1 production |
| AU2008314979A1 (en) | 2007-10-23 | 2009-04-30 | Institute Of Medicinal Molecular Design, Inc. | Inhibitor of PAI-1 production |
| US8277845B2 (en) | 2007-12-04 | 2012-10-02 | Remedy Pharmaceuticals, Inc. | Formulations and methods for lyophilization and lyophilates provided thereby |
| GB0724340D0 (en) | 2007-12-13 | 2008-01-30 | Univ Dundee | Novel Therapeutic Agents |
| CA2709784A1 (fr) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Procede permettant de modifier la duree de vie d'organismes eucaryotes |
| US20110034560A1 (en) | 2008-01-29 | 2011-02-10 | Sven Jacobson | Liquid formulations of compounds active at sulfonylurea receptors |
| US8211882B2 (en) | 2008-03-08 | 2012-07-03 | Richard Delarey Wood | Glutamate receptor modulators and therapeutic agents |
| WO2009139925A1 (fr) | 2008-05-16 | 2009-11-19 | Panacea Pharmaceuticals, Inc. | Procédés pour le traitement d'un œdème cérébral |
| WO2010033560A2 (fr) | 2008-09-16 | 2010-03-25 | University Of Maryland, Baltimore | Inhibiteurs de sur1 pour la thérapie |
| WO2010048273A2 (fr) | 2008-10-21 | 2010-04-29 | President And Fellows Of Harvard College | Procédés et composés pour le traitement de troubles neurodégénératifs |
| GB0823366D0 (en) | 2008-12-22 | 2009-01-28 | Uni I Oslo | Synthesis |
| WO2010079406A1 (fr) | 2009-01-12 | 2010-07-15 | Purapharm International (Hk) Limited | Composés et leurs utilisations pour le traitement d'inflammations et la modulation de réponses immunitaires |
| US20120039805A1 (en) | 2009-02-20 | 2012-02-16 | Pangea Biosciences, Inc. | Therapeutics And Methods For Treating Neoplastic Diseases Comprising Determining The Level Of Caveolin-1 And/Or Caveolin-2 In A Stromal Cell Sample |
| RU2564900C2 (ru) | 2010-03-10 | 2015-10-10 | Дзе Юниверсити Оф Флорида Рисерч Фаундейшн, Инк. | Модулирование аквапоринов релаксином |
| CN109172363A (zh) | 2010-07-19 | 2019-01-11 | 比根切萨彼公司 | 静脉内施用格列苯脲和其他药物的方法 |
| JP2013535457A (ja) * | 2010-07-28 | 2013-09-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器系及び炎症性疾患の治療用医薬組成物 |
| US20110052678A1 (en) | 2010-11-05 | 2011-03-03 | Shantha Totada R | Method for treating age related macular degeneration |
| EP2685972A4 (fr) | 2011-03-14 | 2014-08-13 | Io Therapeutics Inc | Traitement d'une inflammation et de troubles auto-immuns en utilisant des agonistes sélectifs du rar alpha |
| EP2717883B1 (fr) * | 2011-05-02 | 2017-03-22 | Stichting VUmc | Protection contre un dysfonctionnement de la barrière endothéliale par l'inhibition du gène associé à la tyrosine kinase abl (arg) |
| RU2461375C1 (ru) * | 2011-05-19 | 2012-09-20 | Учреждение Российской академии медицинских наук Научно-исследовательский институт онкологии Сибирского отделения Российской академии медицинских наук (НИИ онкологии СО РАМН) | Способ комбинированного лечения больных местно-распространенным раком желудка |
| WO2013152313A1 (fr) * | 2012-04-05 | 2013-10-10 | The Regents Of The University Of California | Compositions et méthodes de traitement du cancer, de maladies et d'états sensibles à l'inhibition d'un facteur de croissance |
| EP2844345B1 (fr) | 2012-05-04 | 2022-08-03 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Modulateurs du récepteur de relaxine 1 |
| WO2013169939A2 (fr) | 2012-05-08 | 2013-11-14 | Aeromics, Llc | Nouveaux procédés |
| WO2015037659A1 (fr) | 2013-09-13 | 2015-03-19 | 株式会社医薬分子設計研究所 | Préparation de solution aqueuse et son procédé de fabrication |
| WO2015069961A1 (fr) | 2013-11-06 | 2015-05-14 | Aeromics, Llc | Nouveaux sels de promédicament |
| DK3080134T3 (en) | 2013-12-13 | 2018-10-22 | Vertex Pharma | PRODRUGS OF PYRIDONAMIDS USED AS MODULATORS OF SODIUM CHANNELS |
| US20180042873A1 (en) | 2014-11-13 | 2018-02-15 | Aeromics, Inc. | Novel methods |
| ES2927482T3 (es) | 2015-05-29 | 2022-11-07 | Univ Maryland | Métodos para reducir o prevenir el daño de la íntima causado por la estimulación mecánica de las células endoteliales |
| ES2940669T3 (es) | 2015-10-07 | 2023-05-10 | Biogen Chesapeake Llc | Métodos de tratamiento de lesiones o afecciones relacionadas con edema del SNC |
| RU2018144043A (ru) | 2016-05-13 | 2020-06-15 | Аэромикс, Инк. | Кристаллы |
| CN109689037B (zh) | 2016-07-29 | 2022-09-13 | 生物切萨皮克有限责任公司 | 利用sur1-trpm4通道抑制剂的医学治疗方法 |
-
2014
- 2014-11-06 WO PCT/US2014/064447 patent/WO2015069961A1/fr active Application Filing
- 2014-11-06 WO PCT/US2014/064441 patent/WO2015069956A2/fr active Application Filing
- 2014-11-06 MX MX2016006012A patent/MX2016006012A/es unknown
- 2014-11-06 AU AU2014346682A patent/AU2014346682B2/en active Active
- 2014-11-06 ES ES14859359T patent/ES2834131T3/es active Active
- 2014-11-06 CN CN202011275472.XA patent/CN112402434A/zh active Pending
- 2014-11-06 US US15/034,543 patent/US9949991B2/en active Active
- 2014-11-06 JP JP2016552486A patent/JP6535338B2/ja active Active
- 2014-11-06 US US15/035,006 patent/US20160279155A1/en not_active Abandoned
- 2014-11-06 CN CN202011275350.0A patent/CN112370456A/zh active Pending
- 2014-11-06 WO PCT/US2014/064432 patent/WO2015069948A1/fr active Application Filing
- 2014-11-06 EP EP14859943.4A patent/EP3065728A4/fr not_active Withdrawn
- 2014-11-06 SG SG11201604153UA patent/SG11201604153UA/en unknown
- 2014-11-06 US US15/034,274 patent/US9827253B2/en active Active
- 2014-11-06 JP JP2016552485A patent/JP2016535787A/ja not_active Ceased
- 2014-11-06 RU RU2016121850A patent/RU2691951C2/ru active
- 2014-11-06 CA CA2929821A patent/CA2929821A1/fr active Pending
- 2014-11-06 KR KR1020167014998A patent/KR20160079109A/ko not_active Application Discontinuation
- 2014-11-06 CN CN201480061066.XA patent/CN106163506A/zh active Pending
- 2014-11-06 EP EP14860390.5A patent/EP3065729A4/fr active Pending
- 2014-11-06 EP EP14859359.3A patent/EP3065727B1/fr active Active
-
2016
- 2016-05-02 IL IL245420A patent/IL245420B/en active IP Right Grant
- 2016-05-06 MX MX2021008629A patent/MX2021008629A/es unknown
- 2016-11-04 HK HK16112696.4A patent/HK1224228A1/zh unknown
-
2017
- 2017-10-24 US US15/792,707 patent/US10258636B2/en active Active
-
2018
- 2018-12-31 US US16/236,817 patent/US10894055B2/en active Active
-
2019
- 2019-05-31 JP JP2019102367A patent/JP6957557B2/ja active Active
- 2019-10-28 US US16/665,333 patent/US11071744B2/en active Active
-
2020
- 2020-06-01 AU AU2020203697A patent/AU2020203697A1/en not_active Abandoned
- 2020-11-16 US US17/099,435 patent/US11801254B2/en active Active
-
2021
- 2021-06-16 US US17/304,201 patent/US20220143048A1/en active Pending
- 2021-10-06 JP JP2021164647A patent/JP2022003084A/ja active Pending